CRISPR obtained approval for Casgevy back in 2023, but the rollout has been slow. In 2025, the company incurred a loss of more than $580 million. Its cash position, however, remains strong.

CRISPR Therapeutics recently reported that rollout of its approved gene therapy Casgevy for sickle cell disease and transfusion‑dependent beta thalassemia has been slower than hoped, contributing to a ...

CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

In the latest close session, CRISPR Therapeutics AG (CRSP) was down 8.7% at $55.52. The stock fell short of the S&P 500, which registered a gain of 0.03% for the day. On the other hand, the Dow ...

CRISPR Therapeutics AG (NASDAQ:CRSP) also received a rating update from JPMorgan on February 16. The firm cut the price ...

CRISPR Therapeutics AG (NASDAQ: CRSP) stock is up more than 12% after the gene editing pioneer reported its Q4 2025 earnings ...

CRISPR Therapeutics reached a significant milestone a couple of years ago: its first product approval. The company’s stock, once a highflier, has declined from its peak. CRISPR Therapeutics (NASDAQ: ...

Gene therapy and gene editing are marvels of modern biotechnology, providing revolutionary techniques for fixing genetic abnormalities. Gene therapy introduces functional genetic material to ...

Regulatory tailwinds and weak earnings set the stage The FDA's draft guidance to speed approval of genome editing and RNA therapies has put CRISPR Therapeutics (CRSP) in focus, even as the company ...

Cathie Wood aims to identify innovators and invest in them early in their stories. Wood has been regularly adding to her position in this stock, and it’s one of her top holdings. 10 stocks we like ...